ClinicalTrials.gg
RecruitingNCT06898515FASTR-IIUpdated Oct 13, 2026

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

An interventional study of Reprieve System and furosemide infusion in Acute Decompensated Heart Failure, sponsored by Reprieve Cardiovascular, Inc. Recruiting at 50 sites in 5 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Reprieve Cardiovascular, Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 13, 2026Start date movedDesign changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
297th of 1,602
400 · median 66
Started
2025
with 107 others
No phase
887 of 2,159
159 open now
Primary completion
2027-08
later than 220 of 438 live
Registered
1,995th of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 297th largest by planned enrollment of the 1,602 interventional ones that give a count, is one of 108 that started in 2025, is one of 887 with no phase, reaches primary completion later than 220 of the 438 other live ones, and was the 1,995th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.

03

Conditions studied

  • Acute Decompensated Heart Failure

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of HF with expected hospitalization >24 hours, with >1 new or worsening symptom and >2 physical examination, laboratory, or invasive findings of HF, and receiving or with plans to receive a HF-specific treatment
  2. ≥10 lb. (4.5 kg) above dry weight as estimated by health care provider.
  3. Current outpatient prescription for daily loop diuretic.
  4. Participants ≥ 22 years of age able to provide and comply with study procedures.
  5. Elevated risk of diuretic resistance, as indicated by at least one of the following: Baseline hypochloremia OR Urine output \<1L in the 6 hours following IV loop diuretic >=40 mg furosemide equivalent OR Spot urine sodium \<100 mmol/L 1-2 hours after IV loop diuretic >= 40 mg furosemide equivalent

Exclusion criteria

Exclusion Criteria:

  1. Urologic issues that would predispose the participant to a high rate of urogenital trauma or infection with catheter placement or known inability to place a Foley catheter.
  2. Hemodynamic instability as defined by any of the following: sustained systolic blood pressure \<90 mmHg for >15 minutes within the past 48 hours, use of IV vasopressors or inotropes within past 48 hours, and/or current or previous mechanical circulatory support within the last week.
  3. Uncontrolled arrhythmias defined as sustained HR >130 beats/min for >10 minutes within the past 48 hours.
  4. Severe lung disease with chronic home oxygen requirement >2L/min.
  5. Acute infection with evidence of systemic involvement (e.g., clinically suspected infection with fever or elevated serum white blood cell count).
  6. Estimated (eGFR) \<25 ml/min/1.73m2 (calculated with either MDRD or CKD-EPI) or current use of renal replacement therapy (RRT).
  7. Significant left ventricular outflow obstruction, severe uncorrected complex congenital heart disease, known severe stenotic valvular disease, severe infiltrative or constrictive cardiomyopathy or other diagnosis that would make aggressive decongestion unsafe.
  8. Current or recent (\< 30 days) type I myocardial infarction (e.g., acute coronary syndrome such as NSTEMI or STEMI from plaque rupture), coronary artery bypass surgery, or stroke. An isolated troponin elevation (e.g., from volume overload or demand ischemia) is not a reason for exclusion.
  9. Severe electrolyte abnormalities (e.g., serum potassium \<3.0 mEq/L, magnesium \<1.3 mEq/L or sodium \<125 mEq/L). Note: These are based on baseline/screening labs. Participants whose electrolyte levels are repleted cannot be reassessed for inclusion in the trial.
  10. Other concomitant disease or condition the investigator believes will make it difficult to follow instructions or comply with study procedures and/or follow-up visits, including expected prolonged hospitalization for reasons other than decongestive therapy
  11. Currently enrolled in an interventional trial (observational studies are permitted).
  12. less than 6 months.
  13. Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Reprieve System

    Participants randomized to Reprieve System will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.

    Device: Reprieve System

  • Active comparator
    Optimal Diuretic Therapy (ODT)

    Participants randomized to ODT will be treated with guided diuretic titration, as recommended in the ESC guidelines on diuretic therapy

    Drug: furosemide infusion

  • No intervention
    Registry

    Participants will be treated per local site usual care.

Interventions

  • DeviceReprieve System

    The Reprieve System is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.

  • DrugFurosemideStudies of FurosemideFurosemide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants randomized to ODT will be treated with guided diuretic titration, as recommended in the ESC guidelines on diuretic therapy

06

What researchers measure

Primary outcomes

  1. Hierarchical composite/win-ratio

    1. Freedom from 30-day CV mortality 2. Freedom from HF Rehospitalization 30 days post-discharge 3. Greater net sodium loss per 24 hours during treatment

    Time frame: 1. up to 30 days from randomization, 2. up to 30 days from discharge, 3. up to 72 hours after randomization

  2. Incidence of device/procedure-related adverse events (KDIGO stage 2 or greater AKI, CAUTI)

    KDIGO stage 2 or greater AKI: ≥ doubling of serum creatinine or use of renal replacement therapy; CAUTI per CDC definition

    Time frame: initiation of randomized therapy through 72 hours following completion of randomized therapy

Secondary outcomes

  1. Net sodium loss

    Time frame: per 24 hours at end of randomized therapy

  2. Time to discharge readiness

    Time from initiation of randomized therapy to when the participant becomes medically ready for discharge from a decompensated heart failure treatment standpoint

    Time frame: through hospital discharge, an average of 5 days

  3. Time on IV diuretic therapy

    Time frame: randomization through hospital discharge, assessed up to 30 days

  4. Net fluid loss

    Fluid input subtracted from total urine output

    Time frame: per 24 hours at end of randomized therapy

  5. Weight loss

    Time frame: per 24 hours at end of randomized therapy

  6. CV mortality and cumulative HF rehospitalizations

    Both types of events will be combined in a total "event rate" compared between groups

    Time frame: 90 days after hospital discharge

  7. Length of stay

    Time from initiation of randomized therapy to hospital discharge

    Time frame: through hospital discharge, an average of 5 days

  8. Hypotension defined as systolic blood pressure < 80 mmHg documented with two readings at least 30 minutes apart with symptoms (e.g., chest pain, dizziness) or <80 mmHg requiring an intervention including IV fluids or vasopressors.

    Time frame: initiation of randomized therapy up to 12 hours after stopping randomized therapy

  9. Severe electrolyte abnormality

    serum potassium \<3.0 mEq/L with ≥ 0.5 mEq/L decrease from initiation of randomized therapy, magnesium \<1.3 mEq/L with ≥0.5 mEq/L decrease from initiation of randomized therapy, or sodium \<125 mEq/L with ≥ 5.0 mEq/L decrease from initiation of randomized therapy

    Time frame: initiation of randomized therapy up to 72 hours after stopping randomized therapy

  10. Worsening heart failure requiring a higher level of HF therapy

    Time frame: initiation of randomized therapy up to 72 hours after stopping randomized therapy

  11. Tinnitus or hearing loss lasting more than 30 minutes

    Time frame: initiation of randomized therapy up to 12 hours after stopping randomized therapy

07

Study locations

49 of 50 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Aug 2027, 25 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 25 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 27, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 7 sites removed. 7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • University of Louisville Hospital · Louisville, United StatesNot yet recruiting→Recruiting
  • Duke University · Durham, United StatesNot yet recruiting→Recruiting
  • Moses H. Cone Memorial Hospital · Greensboro, United StatesNot yet recruiting→Recruiting
  • Aurora St. Luke's Medical Center · Milwaukee, United StatesNot yet recruiting→Recruiting
  • Universitaria delle Marche · Ancona, ItalyNot yet recruiting→Recruiting
  • ASST Azienda Ospedaliera Papa Giovanni XXIII · Bergamo, ItalyNot yet recruiting→Recruiting
  • ASST Niguarda Great Metropolitan Hospital · Milan, ItalyNot yet recruiting→Recruiting
Show 4 added (4 United States)
  • Memorial Care Long Beach · Long Beach, United States
  • Wellstar Hospital · Atlanta, United States
  • Vanderbilt University Medical Center · Nashville, United States
  • Houston Methodist · Houston, United States
Show 7 removed
  • Scripps Memorial Hospital · La Jolla, United States
  • Harry S. Truman Veteran's Memorial Hospital · Columbia, United States
  • University of Nebraska Medical Center · Omaha, United States
  • Stony Brook University Hospital · Stony Brook, United States
  • University of Cincinnati · Cincinnati, United States
  • UW Harborview · Seattle, United States
  • Jena University Hospital · Jena, Germany
Oct 8, 2026
Start date
Jul 14, 2025→Jul 28, 2025
Oct 13, 2026
Design
Phase 3→Not applicable
Oct 13, 2026
Show all 2 updates
  1. Oct 13, 2026
    Start date Jul 14, 2025→Jul 28, 2025
    Design Phase 3→Not applicable
    + 1 other change: site details
  2. Oct 8, 2026
    4 sites added, 7 sites removed. 7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • University of Louisville Hospital · Louisville, United StatesNot yet recruiting→Recruiting
    • Duke University · Durham, United StatesNot yet recruiting→Recruiting
    • Moses H. Cone Memorial Hospital · Greensboro, United StatesNot yet recruiting→Recruiting
    • Aurora St. Luke's Medical Center · Milwaukee, United StatesNot yet recruiting→Recruiting
    • Universitaria delle Marche · Ancona, ItalyNot yet recruiting→Recruiting
    • ASST Azienda Ospedaliera Papa Giovanni XXIII · Bergamo, ItalyNot yet recruiting→Recruiting
    • ASST Niguarda Great Metropolitan Hospital · Milan, ItalyNot yet recruiting→Recruiting
    Show 4 added (4 United States)
    • Memorial Care Long Beach · Long Beach, United States
    • Wellstar Hospital · Atlanta, United States
    • Vanderbilt University Medical Center · Nashville, United States
    • Houston Methodist · Houston, United States
    Show 7 removed
    • Scripps Memorial Hospital · La Jolla, United States
    • Harry S. Truman Veteran's Memorial Hospital · Columbia, United States
    • University of Nebraska Medical Center · Omaha, United States
    • Stony Brook University Hospital · Stony Brook, United States
    • University of Cincinnati · Cincinnati, United States
    • UW Harborview · Seattle, United States
    • Jena University Hospital · Jena, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06898515
Lead sponsor
Reprieve Cardiovascular, Inc
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Jul 28, 2025
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Annemarie Forrest
Contact
aforrest@reprievecardio.com
617-848-0400
Javed Butler, MD, MPH, MBA
principal investigator · Baylor Scott and White Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion